2,988 Shares in Amgen Inc. $AMGN Purchased by ING Groep NV

ING Groep NV purchased a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,988 shares of the medical research company’s stock, valued at approximately $978,000.

Other institutional investors also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. increased its position in shares of Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC bought a new stake in shares of Amgen during the fourth quarter valued at approximately $1,669,000. Adell Harriman & Carpenter Inc. increased its position in shares of Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after acquiring an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Amgen during the fourth quarter valued at approximately $22,441,000. Finally, Sigma Planning Corp increased its position in shares of Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after acquiring an additional 3,488 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
• Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
• Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
• Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
• Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Amgen Stock Down 2.0%

Amgen stock opened at $337.73 on Thursday. The stock has a market cap of $182.28 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 3.46 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The stock has a fifty day moving average of $340.89 and a 200 day moving average of $345.53.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the firm earned $4.90 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.38 EPS for the current year.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.85% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AMGN. Leerink Partners reissued a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Erste Group Bank restated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Canaccord Genuity Group started coverage on shares of Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 target price for the company. Finally, Morgan Stanley boosted their target price on shares of Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $354.12.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.